Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate ... changes to the proposed structure of the Business Combination that may be required or ...